From the publishers of JADPRO

MPN Resource Center


Welcome to the JADPRO MPN Resource Center! We’ve expanded our previous platform to provide you more information, education, and cutting-edge research from the field of myeloproliferative neoplasms. We’re excited to provide this expanded offering to you and your colleagues. Take a look around, and send us your feedback to

Lindsey Lyle, MS, PA-C, Senior Instructor, Blood Cancers and Bone Marrow Transplant Program, University of Colorado, Anschutz Medical Campus

News & Literature Highlights

American Journal of Hematology

Cerebral venous thrombosis and myeloproliferative neoplasms: A three-center study of 74 consecutive cases

Clinical Lymphoma Myeloma and Leukemia

Mortality and causes of death of patients with polycythemia vera: analysis of the REVEAL prospective, observational study

Annals of Hematology

Evaluation of the need for cytoreduction and its potential carcinogenicity in children and young adults with myeloproliferative neoplasms

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Treatment outcomes and antibody immunity to SARS-CoV-2 in patients with hematological malignancies

European Society for Medical Oncology (ESMO) Congress 2021 Abstract

Final results of a phase II study of tipifarnib in chronic myelomonocytic leukemia (CMML) and other myelodysplastic/myeloproliferative neoplasms (MDS/MPN)

BMC Cancer

Tobacco use in the myeloproliferative neoplasms: symptom burden, patient opinions, and care

International Society on Thrombosis and Haemostasis 2021 Congress (Abstract)

Thrombotic complications in a cohort of children with myeloproliferative neoplasms

Journal of Cardiovascular Pharmacology

NOAC in patients with VTE and polycythemia vera or essential thrombocythemia

Frontiers in Immunology

Allogeneic hemopoietic stem cell transplantation for myelofibrosis: 2021

Journal of Hematology & Oncology

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution